Literature DB >> 1791077

Nosocomial pneumonia: comparative multicentre trial between monotherapy with cefotaxime and treatment with antibiotic combinations.

M Fernández-Guerrero1, F Gudiol, A Rodriguez-Torres, C Arnau, L Valdés, C Vallvé.   

Abstract

In a multicentre clinical trial involving 32 hospitals, 588 adult patients diagnosed with nosocomial pneumonia and not receiving mechanical ventilation were treated randomly with monotherapy with cefotaxime or the antibiotic combination routinely used in each particular hospital. Both groups of patients were similar regarding demographic data, concurrent diseases, additional therapies and causative organism. Protocol violations were recorded in 40 patients, and these patients were excluded from the evaluation of treatment efficacy. The cure rate was 79% in the cefotaxime group and 71% in the group receiving antibiotic combinations; this difference is statistically significant (p = 0.03, Fisher's two-tailed test). In the patients receiving combinations of cephalosporins having activity predominantly against gram-positive organisms plus aminoglycosides, the cure rate obtained was very low. The frequency of serious adverse reactions was significantly higher in the group treated with antibiotic combinations. It is concluded that monotherapy with cefotaxime is the regimen that offers better results for the empirical treatment of nosocomial pneumonia.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1791077     DOI: 10.1007/bf01715772

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  12 in total

Review 1.  Antibiotic combinations: should they be tested?

Authors:  G M Eliopoulos; C T Eliopoulos
Journal:  Clin Microbiol Rev       Date:  1988-04       Impact factor: 26.132

2.  A fiberoptic bronchoscopy technique to obtain uncontaminated lower airway secretions for bacterial culture.

Authors:  N Wimberley; L J Faling; J G Bartlett
Journal:  Am Rev Respir Dis       Date:  1979-03

Review 3.  Cefotaxime. An update of its pharmacology and therapeutic use.

Authors:  P A Todd; R N Brogden
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

4.  Ceftazidime versus tobramycin-ticarcillin in the treatment of pneumonia and bacteremia.

Authors:  L A Cone; D R Woodard; D S Stoltzman; R G Byrd
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

5.  Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia.

Authors:  R D Moore; C R Smith; P S Lietman
Journal:  Am J Med       Date:  1984-10       Impact factor: 4.965

6.  Pneumonia treated with imipenem/cilastatin.

Authors:  R A Salata; R L Gebhart; D L Palmer; B H Wade; W M Scheld; D H Groschel; R P Wenzel; G L Mandell; R J Duma
Journal:  Am J Med       Date:  1985-06-07       Impact factor: 4.965

7.  Deaths from nosocomial infections: experience in a university hospital and a community hospital.

Authors:  P A Gross; H C Neu; P Aswapokee; C Van Antwerpen; N Aswapokee
Journal:  Am J Med       Date:  1980-02       Impact factor: 4.965

8.  Comparison of ceftriaxone with cefotaxime in serious chest infections.

Authors:  J H Reeves; G M Russell; J F Cade; M McDonald
Journal:  Chest       Date:  1989-12       Impact factor: 9.410

Review 9.  Cefotaxime. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-03       Impact factor: 9.546

10.  Aztreonam therapy for gram-negative pneumonia.

Authors:  R N Greenberg; P M Reilly; K L Luppen; M Bollinger; R McMillian
Journal:  Am J Med       Date:  1985-02-08       Impact factor: 4.965

View more
  10 in total

1.  Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.

Authors:  Andre C Kalil; Mark L Metersky; Michael Klompas; John Muscedere; Daniel A Sweeney; Lucy B Palmer; Lena M Napolitano; Naomi P O'Grady; John G Bartlett; Jordi Carratalà; Ali A El Solh; Santiago Ewig; Paul D Fey; Thomas M File; Marcos I Restrepo; Jason A Roberts; Grant W Waterer; Peggy Cruse; Shandra L Knight; Jan L Brozek
Journal:  Clin Infect Dis       Date:  2016-07-14       Impact factor: 9.079

2.  Retrospective analysis of risk factors and prognosis in non-ventilated patients with nosocomial pneumonia.

Authors:  J Gómez; A Esquinas; M D Agudo; J M Sánchez Nieto; M L Núñez; V Baños; M Canteras; M Valdes
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-03       Impact factor: 3.267

Review 3.  Antibiotics in neonatal infections: a review.

Authors:  V Fanos; A Dall'Agnola
Journal:  Drugs       Date:  1999-09       Impact factor: 9.546

Review 4.  Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis.

Authors:  Mical Paul; Adi Lador; Simona Grozinsky-Glasberg; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2014-01-07

Review 5.  Cefotaxime. A reappraisal of its antibacterial activity and pharmacokinetic properties, and a review of its therapeutic efficacy when administered twice daily for the treatment of mild to moderate infections.

Authors:  R N Brogden; C M Spencer
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

6.  Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group.

Authors:  M P Fink; D R Snydman; M S Niederman; K V Leeper; R H Johnson; S O Heard; R G Wunderink; J W Caldwell; J J Schentag; G A Siami
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

Review 7.  Adverse effects of newer cephalosporins. An update.

Authors:  J W Thompson; R F Jacobs
Journal:  Drug Saf       Date:  1993-08       Impact factor: 5.606

Review 8.  Drug utilisation review (DUR) of the third generation cephalosporins. Focus on ceftriaxone, ceftazidime and cefotaxime.

Authors:  A Adu; C L Armour
Journal:  Drugs       Date:  1995-09       Impact factor: 9.546

9.  Clinical practice guidelines for hospital-acquired pneumonia and ventilator-associated pneumonia in adults.

Authors:  Coleman Rotstein; Gerald Evans; Abraham Born; Ronald Grossman; R Bruce Light; Sheldon Magder; Barrie McTaggart; Karl Weiss; George G Zhanel
Journal:  Can J Infect Dis Med Microbiol       Date:  2008-01       Impact factor: 2.471

Review 10.  Guidelines for the management of hospital-acquired pneumonia in the UK: report of the working party on hospital-acquired pneumonia of the British Society for Antimicrobial Chemotherapy.

Authors:  R G Masterton; A Galloway; G French; M Street; J Armstrong; E Brown; J Cleverley; P Dilworth; C Fry; A D Gascoigne; Alan Knox; Dilip Nathwani; Robert Spencer; Mark Wilcox
Journal:  J Antimicrob Chemother       Date:  2008-04-29       Impact factor: 5.790

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.